Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
- Volatility is at a recent 2 week low. A recent low volatility of stock movement within a box range could trigger break through when activities pick up.
- A moving average of short volume ratio is at a recent 2 week low. A lower short volume ratio could be a bullish signal.
|Earning Growth (QoQ)|
|Revenue Growth (QoQ)|
|Held by Institutions %||55%|
|1 Day Vol Adjusted Return||0.4|
|1 Month Vol Adjusted Return||4.1|
|3 Month Vol Adjusted Return||11.6|
|6 Month Vol Adjusted Return||12.5|
|20 Days SMA Price ZScore||0.3|
|50 Days SMA Price ZScore||1.3|
|12 -26 Days PPO||8.2|
|1 Month Average Short Volume Ratio||54.5|
|1 Day Volume Change ZScore||-1.0|
|1 Month Daily Vol||8.4|
Company to Hold R&D Day on Thursday, March 11, 2021BOSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (the “Company”) (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast to discuss financial results for the fourth quarter and full year 2020 on Thursday, February 25, 2021 at 4:30pm EDT. The live call can be accessed by dialing 1-877-451-6152 (U.S. and Canada) or 1-201-389-0879 (International). The passcode for the conference call is 13715482. The liv...
Shares of ZIOPHARM Oncology (NASDAQ:ZIOP) saw some unusual options activity on Monday. Following the unusual option alert, the stock price moved up to $5.61. Sentiment: BULLISH Option Type: TRADE Trade Type: CALL Expiration Date: 2022-01-21 Strike Price: $7.00 Volume: 957 Open Interest: 4778 Three Ways Options Activity Is ‘Unusual' One way options market activity can be considered unusual is when volume is exceptionally higher than its historical average. The volume of options activity refers to...
Shares of Ziopharm Oncology (NASDAQ: ZIOP) were soaring 11.8% as of 11:45 a.m. EST on Friday. The nice gain came after the company announced the election of Robert Postma to its board of directors. The addition expanded Ziopharm's board from eight members to nine.
BOSTON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced the election of Robert Postma to its Board of Directors (the “Board”), effective immediately. Mr. Postma is the Founder of WaterMill Asset Management, a sizeable and long-term shareholder of Ziopharm. James Huang, Chairman of the Board, said, “We welcome Bob to Ziopharm’s Board of Directors. With his experience and financial acumen, Bob will make an immediate contribution...
– Mr. Huang is a veteran industry entrepreneur with 20+ years founding and funding biotech innovation – – Heidi Hagen elected Lead Independent Director –BOSTON, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP) today announced the election of James Huang as Chairman of the Board of Directors (the “Board”), effective immediately.Mr. Huang has served on the Board since July 2020 and is currently a Managing Partner at Kleiner Perkins Caufield & ...
BOSTON, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the H.C. Wainwright Bioconnect 2021 Conference and will deliver a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference. H.C. Wainwright Bioconnect 2021 Conference Date: Monday, January 11, 2021 Time: 6:00 am ET (access to on dem...